## FIVE: Five Below, Inc. - XLY: Consumer Cyclical

### Executive Summary

VALUE thesis: PEG 1.32 indicates fundamental undervaluation. Quality metrics strong (ROE 17%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($159.70)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 3, Bearish: 1)

**1. Five Below, Inc. (NASDAQ:FIVE) Q3 2025 Earnings Call Transcript**
- Source: Insider Monkey | 20251205T034401 | Bullish | Relevance: 100%
- Five Below, Inc. (NASDAQ:FIVE) exceeded Q3 2025 earnings expectations with strong sales growth and comparable sales increasing by over 14%, driven by both transactions and ticket. The company's customer-centric strategy focusing on Gen Alpha, Gen Z, and millennials, combined with effective marketing shifts to social media and a flexible pricing strategy beyond the $5 limit, contributed to these robust results. Five Below also provided an optimistic outlook for the fourth quarter and full fiscal year 2025, anticipating continued growth both in sales and store count.

**2. Five Below, Inc. Announces Third Quarter Fiscal 2025 Financial Results**
- Source: Licensing International | 20251204T034401 | Bullish | Relevance: 100%
- Five Below, Inc. reported strong financial results for the third quarter of fiscal 2025, with net sales increasing by 23.1% to $1.0 billion and comparable sales up by 14.3%. The company also increased its full-year 2025 sales and EPS outlook, reflecting confidence in its customer-centric strategy and positive momentum heading into the holiday season. CEO Winnie Park attributed the success to delivering trend-right merchandise, effective marketing, and engaging shopping experiences.

**3. Important Notice to Long-Term Shareholders of Five Below, Inc. (NASDAQ: FIVE); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf**
- Source: GlobeNewswire | 20251204T034401 | Bearish | Relevance: 100%
- Grabar Law Office is investigating potential claims on behalf of long-term shareholders of Five Below, Inc. (NASDAQ: FIVE), Molina Healthcare, Inc. (NYSE: MOH), Synopsys, Inc. (NASDAQ: SNPS), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY). These investigations stem from alleged securities fraud and breaches of fiduciary duty by company officers and directors, impacting shareholders who held stock prior to specific dates. Shareholders are encouraged to contact the firm to potentially seek corporate reforms and the return of funds without personal cost.

**4. HALPER SADEH LLC ENCOURAGES FIVE BELOW, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS**
- Source: KXAN Austin | 20251205T142700 | Somewhat-Bearish | Relevance: 100%
- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Five Below, Inc. (NASDAQ: FIVE) breached their fiduciary duties to shareholders. Long-term shareholders of Five Below are encouraged to contact the firm to discuss potential corporate governance reforms, the return of funds to the company, or other relief. The firm offers to handle the action on a contingent fee basis.

**5. UBS Maintains Five Below (FIVE) Buy Recommendation**
- Source: Nasdaq | 20251204T190400 | Bullish | Relevance: 100%
- UBS has re-affirmed its Buy recommendation for Five Below (FIVE), with an average one-year price target of $167.20, suggesting a 2.48% upside. Institutional ownership in Five Below shows a slight increase in the number of funds, but a decrease in total shares owned by institutions over the last quarter, while the put/call ratio indicates a bullish outlook for the stock. The company's projected annual revenue is expected to increase by 9.93% to $4,866MM, although non-GAAP EPS is projected to decrease by 2.03%.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 17, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Jefferies | $215 | $185 | +16% |
| 2025-12-04 | Citigroup | $175 | $150 | +17% |
| 2025-12-04 | Truist Securiti | $179 | $168 | +7% |
| 2025-12-04 | Goldman Sachs | $188 | $162 | +16% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Jefferies | main | Buy |
| 2025-12-04 | Citigroup | main | Neutral |
| 2025-12-04 | Truist Securiti | main | Hold |
| 2025-12-04 | Goldman Sachs | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.12M) |
| Sells | 7 ($1.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.0% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (+1.3%)
- Blackrock Inc.: 9.1% (-5.9%)
- FMR, LLC: 4.0% (+1.7%)
- Shaw D.E. & Co., Inc: 3.8% (-28.0%)
- American Century Com: 3.4% (+21.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 17 raises (avg +10%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Forward P/E 27.6x stretched relative to 6% growth. Analyst sentiment positive (17 raises, avg +10%). Insider selling cluster ($2.0M in 90 days), potential headwind. Institutional flow bearish (5 selling vs 5 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $10.5B |
| Beta | 1.17 |
| 52W Range | $52.38 - $192.45 |
| Short Interest | 4.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 27.6 |
| Current P/E | 29.4 |
| YoY Growth | 6.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from 3.8% to 8.3% (+4.5% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 93rd percentile. MRS_5 at 4.3% confirms short-term momentum alignment. AM_20 at 10.8% shows strong absolute momentum above own 20MA. Outperforming sector by 7.9pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.75), confirming momentum. Elevated volume (2.6x 20MA), institutional activity likely. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 8.29% (CS: 94) | Strong |
| RSI_14 | 68.7 | Neutral |
| MACD Histogram | 1.75 | Bullish |
| vs SMA20 | 1.108x | Above |
| vs SMA50 | 1.116x | Above |
| vs SMA200 | 1.411x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $173.20
- **Stop Loss:** $159.70 (7.8% risk)
- **Target:** $200.20 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $12,816.80
- **Portfolio %:** 12.82%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-03-18 (Est: $3.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $0.26 | $0.68 | +165.4% |
| 2025Q3 | $0.63 | $0.81 | +29.4% |
| 2025Q2 | $0.83 | $0.86 | +3.4% |
| 2025Q1 | $3.37 | $3.48 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*